Immatics N.V

NASDAQ:IMTX 3:59:45 PM EDT

11.83

+0.04 (+0.34%)

Market Cap (Intraday)	744.21M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$10.27 Million
Adjusted EPS	-$0.40

See more estimates

10-Day MA	$11.95
50-Day MA	$11.73
200-Day MA	$10.97

See more pivots

Immatics N.V Stock, NASDAQ:IMTX

Paul-Ehrlich-Strasse 15, Tuebingen, Baden Wuerttemberg 72076

Germany

Phone: +49.7071.5397.0

Number of Employees: 198

http://www.immatics.com

Description

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The firm's clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCERâ„¢). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.